Comparisons & New Drugs

How medications compare (Wegovy vs Zepbound, semaglutide vs tirzepatide), plus emerging treatments like retatrutide and oral GLP-1s.

Medical illustration comparing the clinical efficacy of GLP-1 receptor agonists (semaglutide, tirzepatide) with the peptides tesamorelin and sermorelin for weight loss and visceral fat reduction. The infographic highlights that while GLP-1s are proven for weight loss, current clinical evidence does not support tesamorelin or sermorelin as effective routine add-ons for general obesity treatment.

Tesamorelin and Sermorelin With GLP-1s: Do They Help With Weight Loss or Visceral Fat?

Tesamorelin and sermorelin are sometimes promoted as add-ons to GLP-1 medications. Learn what the evidence shows about weight loss, visceral fat, semaglutide, and tirzepatide.

Joshua Silva, MD

Jul 45 min read

An evidence-based comparison chart from Potere Health MD analyzing the new 7.2 mg Wegovy weekly dose. The infographic uses a balance scale to illustrate the trade-off between greater potential weight loss (up to ~20.7%) against a higher side effect risk, specifically highlighting gastrointestinal symptoms and new dysesthesia (skin sensitivity) risks associated with the higher dosage.

New Higher Dose of Wegov (Semaglutide 7.2 mg): FDA Approval, Side Effects, and Dosing Guidance

The FDA has approved a higher weekly dose of Wegovy (semaglutide) at 7.2 mg. While clinical trials show this 3× increase can drive total body weight loss toward 20.7%, it also raises the risk of dose-dependent side effects like dysesthesia and GI distress. With no official titration guidelines yet available, Dr. Joshua Silva discusses how to approach this new dosage safely and who may benefit most from the increase.

Joshua Silva, MD

Mar 233 min read

Simple diagram showing retatrutide acting on GLP-1, GIP, and glucagon receptors, addressing the common question of whether it is a “GLP-3” medication

What Is Retatrutide—and Is It More Effective Than Semaglutide or Tirzepatide for Weight Loss?

Retatrutide is an investigational weight-loss medication often described as a “GLP-3.” This article explains what it is, how it works, how it compares to semaglutide and tirzepatide, safety considerations, FDA status, and whether patients should wait or start treatment now.

Joshua Silva, MD

Jan 87 min read

“A thoughtful woman looks to the side while comparing two weight-loss medications. On the right is a tirzepatide vial labeled GLP-1/GIP with checkmarks for ‘Better Results’ and ‘Less Side Effects.’ Below it is a semaglutide vial labeled GLP-1 with a checkmark for ‘Cost-effective.’”

Zepbound (Tirzepatide) vs. Wegovy (Semaglutide): Which Weight-Loss Medication Is Right for You?

If you’re comparing Zepbound (tirzepatide, GLP-1/GIP) vs. Wegovy (semaglutide, GLP-1) for weight loss, you’re not alone. These two medications are the most effective weight-loss injections available today — and both can help you lose significant weight safely under physician supervision. This guide breaks down how each medication works, how they differ, which one produces more weight loss, what side effects to expect, and how to choose the option that fits your goals, budget,

Joshua Silva, MD

Nov 19, 20255 min read

Comparison chart of Wegovy (semaglutide) vs Zepbound (tirzepatide) effectiveness for weight loss based on NEJM STEP and SURMOUNT trials.

ZepBOUND (Tirzepatide) vs Wegovy (Semaglutide)

Wondering if Zepbound or Wegovy is right for you? Learn how they compare for weight loss, safety, and insurance coverage in Utah.

Joshua Silva, MD

Oct 7, 20253 min read